ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01258270
Recruitment Status : Completed
First Posted : December 10, 2010
Last Update Posted : June 10, 2013
Sponsor:
Collaborator:
ConvaTec Inc.
Information provided by (Responsible Party):
OrthoCarolina Research Institute, Inc.

Brief Summary:
The objective of this study is to determine the safety and effectiveness of the AQUACEL® Ag Surgical Dressing (treatment group) as compared to prepackaged island wound dressings consisting of traditional tape and gauze (control group) for total hip and total knee arthroplasty.

Condition or disease Intervention/treatment Phase
Wound Healing Procedure: Postop Dressing Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing. A Prospective, Randomized Study in Primary Total Joint Arthroplasty.
Study Start Date : December 2010
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: (AQUACEL® Ag Surgical Dressing Procedure: Postop Dressing
The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.

Active Comparator: Standard island gauze and tape dressing
A standard island dressing consists of adhesive tape and gauze.
Procedure: Postop Dressing
A standard island dressing consists of adhesive tape and gauze.




Primary Outcome Measures :
  1. The incidence of postoperative severe skin reactions (defined as blisters) around the surgical incision site [ Time Frame: 4 weeks postop ]
    Wound checks will be performed during the postoperative period in the hospital followed by home healthcare providers. The final wound check will be performed by the surgeon at 4 weeks postoperatively.


Secondary Outcome Measures :
  1. Patient pain and satisfaction (1-100 visual analog scale) [ Time Frame: immediate postop, 5-7 days postop, 4 weeks postop ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients presenting for primary total hip performed through a posterior or posterior-lateral surgical approach or primary total knee arthroplasty
  2. Patients between the ages of 18 and 90
  3. The subject is willing and able to understand, sign and date the study specific patient Informed Consent, to volunteer participation in the study
  4. The subject is having surgery at a Carolinas HealthCare System facility
  5. The subject is psychosocially, mentally and physically able to comply with the requirements of the study

Exclusion Criteria:

  1. Patients presenting for revision total hip or total knee arthroplasty
  2. Patients with topical hypersensitivity or allergy to any disposable components of the dressing system such as: ionic silver, polyurethane film
  3. Any systemic or local active dermatological disease that might interfere with the evaluation of the surgical site such as eczema, psoriasis, skin cancer, scleroderma, chronic urticaria
  4. Patients currently participating in another clinical trial that may affect your participation in this trial
  5. Patients with insurance coverage not included in Gentiva list of payers
  6. Patients residing outside of Gentiva's geographical coverage area
  7. Patients having surgery at a NON-Carolinas HealthCare System facility

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01258270


Locations
United States, North Carolina
OrthoCarolina, PA
Charlotte, North Carolina, United States, 28207
Sponsors and Collaborators
OrthoCarolina Research Institute, Inc.
ConvaTec Inc.
Investigators
Principal Investigator: Bryan D Springer, MD OrthoCarolina, PA

Responsible Party: OrthoCarolina Research Institute, Inc.
ClinicalTrials.gov Identifier: NCT01258270     History of Changes
Other Study ID Numbers: 10-10-01A
First Posted: December 10, 2010    Key Record Dates
Last Update Posted: June 10, 2013
Last Verified: January 2012

Additional relevant MeSH terms:
Carboxymethylcellulose Sodium
Laxatives
Gastrointestinal Agents